May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Early Production of CXCL1/KC in High Risk Corneal Allograft Regulates the Late Production of the T Cell Chemoattractants CXCL9/Mig and CXCL10/IP-10 and Causes Increased Graft Rejection
Author Affiliations & Notes
  • A. Sidani
    Ophthalmic Research, Cole Eye Institute, Cleveland, Ohio
  • F. Collings
    Ophthalmic Research, Cole Eye Institute, Cleveland, Ohio
  • G. Amescua
    Ophthalmic Research, Cole Eye Institute, Cleveland, Ohio
  • X. Yang
    Ophthalmic Research, Cole Eye Institute, Cleveland, Ohio
  • V. L. Perez
    Ophthalmic Research, Cole Eye Institute, Cleveland, Ohio
  • Footnotes
    Commercial Relationships A. Sidani, None; F. Collings, None; G. Amescua, None; X. Yang, None; V.L. Perez, None.
  • Footnotes
    Support KO8-EY014912 HIGHWIRE EXLINK_ID="48:5:178:1" VALUE="EY014912" TYPEGUESS="GEN" /HIGHWIRE -03, Research to Prevent Blindness
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 178. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Sidani, F. Collings, G. Amescua, X. Yang, V. L. Perez; Early Production of CXCL1/KC in High Risk Corneal Allograft Regulates the Late Production of the T Cell Chemoattractants CXCL9/Mig and CXCL10/IP-10 and Causes Increased Graft Rejection. Invest. Ophthalmol. Vis. Sci. 2007;48(13):178. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: We have previously shown that the increased rejection of high risk vascularized corneal allografts correlates with increased recruitment of T cell and the early production of the chemokine CXCL1/KC. The goal of this project is to understand the mechanisms behind this process.

Methods:: Murine orthotopic allogeneic corneal allotransplants (Balb/c to C57BL/6) were performed into non-vascularized and vascularized high risk recipients (day 0). Chemokine production of CXCL1/KC and the T cell chemoattractants CXCL9/Mig and CXCL10/IP-10 were determined by ELISA at days 3, 7, 11 and 14. To study the role of CXCL1/KC, high risk corneal allografts recipients were treated with systemic and subconjunctival injections of KC antisera or control on days -1, 0 1, 3, 5, 7, 9, 11. Neutralization of CXCL1/KC was confirmed in corneal extracts by ELISA. Graft survival was scored and the number of CD4 T cells was quantified by immunohistochemistry. Corneas from non-treated and KC antiserum treated mice were harvested at different time points after surgery and extracts were tested for the presence of CXCL9/Mig and CXCL10/IP-10.

Results:: Rejection of high risk corneal allografts correlated with increased production of CXCL1/KC at day 3 and the up-regulation of the T cell chemoattractants CXCL9/Mig and CXCL10/IP-10 at day 11 after transplantation. In vivo neutralization of CXCL1/KC (confirmed by ELISA) resulted in a 50% graft survival compared to 0% of control treated mice. Increased graft survival correlated with decreased recruitment of CD4 T cells. Moreover, the early blockade of CXCL1/KC resulted in a significant down-regulation of late CXCL9/Mig and CXCL10/IP-10 production in surviving high risk corneal allografts compared to controls.

Conclusions:: The recruitment of T cells and graft rejection in high risk corneal allografts is mediated by the orchestrated production CXC chemokines in the graft. Early CXCL1/KC production regulates this process by controlling the late production of T cell chemoattracants CXCL9/Mig and CXCL10/IP-10. The local neutralization of CXCL1/KC could represent a novel form of therapy that blocks the recruitment of allo-specific T cells into the graft to improve high risk corneal allograft survival.

Keywords: transplantation • immunomodulation/immunoregulation • cornea: basic science 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×